comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 16:14:53 - browse：2797

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： CDC: Uninsured rate hit 'record low' right as states cut Medicaid

WSS

Abbott's new heart device gets FDA advisory panel nod

Influencer to be charged after chaos erupts in New York City's Union Square

Microsoft strikes partnership with Duke Health to advance health AI

For BCIs, commercial hurdles may be bigger than scientific ones

Too many hospitalized Covid

Tome Biosciences co

focus

comprehensive

explore

The high cost of giving birth even with insurance

Gilgo Beach: Police identify another victim in serial killing investigation

Drug repurposing or repositioning? The language matters

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Cancer drug shortages should be causing more outrage

Long Covid research funding gets a major boost from NIH

At least 13 dead in Texas as scorching temps continue

Tome Biosciences co

How one medical school became remarkably diverse

TytoCare raises $49 million to build out AI

hotspot

Tome Biosciences co

My superpower is killing ticks

Long Covid research funding gets a major boost from NIH

Abbott's new heart device gets FDA advisory panel nod

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Resistance to opioid

hotspot

explore

explore

leisure time